SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a tech-enabled biopharma company combining automated, experimental biology with artificial intelligence to discover novel treatments that extend beyond our ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...
SALT LAKE CITY--(BUSINESS WIRE)--Imran S. Haque, Ph.D., a computer scientist by training, has made a name for himself at the intersection of machine learning and biology by maintaining a high standard ...
Bayer and digital biology company Recursion Inc. entered into a strategic collaboration agreement to leverage Recursion’s purpose-built, artificial intelligence-guided drug discovery platform and ...
Recursion, a company that uses machine learning for drug discovery, is partnering with Roche and its subsidiary Genentech to identify novel drug targets and develop drugs against them. The firms will ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 10 most shorted penny stocks to buy. The stock offers a 100% upside potential at the prevailing level, as of April 23 closing, based on its 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results